UTHR United Therapeutics Corporation Stock Quote

UTHR [NASD]

Index	-	P/E	16.34	EPS (ttm)	10.57	Insider Own	0.10%	Shs Outstand	44.40M	Perf Week	4.69%
Market Cap	7.77B	Forward P/E	14.36	EPS next Y	12.04	Insider Trans	0.00%	Shs Float	43.66M	Perf Month	16.60%
Income	468.60M	PEG	-	EPS next Q	3.24	Inst Own	98.50%	Short Float	4.55%	Perf Quarter	52.90%
Sales	1.41B	P/S	5.51	EPS this Y	-117.90%	Inst Trans	-0.10%	Short Ratio	4.70	Perf Half Y	47.46%
Book/sh	73.94	P/B	2.34	EPS next Y	-6.05%	ROA	11.30%	Target Price	156.80	Perf Year	83.60%
Cash/sh	35.15	P/C	4.92	EPS next 5Y	-10.88%	ROE	15.50%	52W Range	75.58 - 171.17	Perf YTD	13.85%
Dividend	-	P/FCF	11.77	EPS past 5Y	-18.90%	ROI	-3.60%	52W High	0.96%	Beta	0.42
Dividend %	-	Quick Ratio	6.90	Sales past 5Y	2.40%	Gross Margin	92.80%	52W Low	128.66%	ATR	5.33
Employees	920	Current Ratio	7.20	Sales Q/Q	-5.30%	Oper. Margin	41.20%	RSI (14)	75.21	Volatility	3.88% 3.07%
Optionable	Yes	Debt/Eq	0.24	EPS Q/Q	27.60%	Profit Margin	33.20%	Rel Volume	1.70	Prev Close	167.26
Shortable	Yes	LT Debt/Eq	0.24	Earnings	Oct 28 BMO	Payout	0.00%	Avg Volume	422.88K	Price	172.82
Recom	2.20	SMA20	11.45%	SMA50	19.80%	SMA200	44.15%	Volume	719,063	Change	3.32%

Sep-14-20

Resumed

JP Morgan

Overweight

$142

Jun-25-20

Reiterated

H.C. Wainwright

Neutral

$85 → $125

Mar-10-20

Upgrade

Jefferies

Hold → Buy

$123

Feb-27-20

Upgrade

Cowen

Market Perform → Outperform

$119 → $145

Jan-31-20

Upgrade

JP Morgan

Neutral → Overweight

$120

Dec-03-19

Initiated

BofA/Merrill

Underperform

Aug-01-19

Upgrade

Ladenburg Thalmann

Neutral → Buy

$103 → $106

Aug-01-19

Upgrade

Jefferies

Underperform → Hold

$90

Jul-01-19

Upgrade

Credit Suisse

Neutral → Outperform

$98 → $101

May-17-19

Upgrade

UBS

Sell → Neutral

$115 → $94

May-09-19

Upgrade

Credit Suisse

Underperform → Neutral

$98

Oct-12-18

Upgrade

Standpoint Research

Hold → Buy

Aug-08-18

Downgrade

Credit Suisse

Neutral → Underperform

Apr-03-18

Upgrade

Credit Suisse

Underperform → Neutral

Feb-22-18

Reiterated

Barclays

Underweight

$115 → $105

Jan-18-18

Resumed

Credit Suisse

Underperform

$118

Dec-27-17

Reiterated

Wedbush

Outperform

$213 → $232

Apr-27-17

Reiterated

Wedbush

Outperform

$229 → $213

Mar-30-17

Initiated

UBS

Sell

$112

Mar-16-17

Initiated

Credit Suisse

Underperform

Jan-13-21 05:01PM	United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease PR Newswire
Jan-07-21 09:28AM	RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation Zacks
Jan-04-21 06:00AM	United Therapeutics Corporation To Present At The 39th Annual J.P. Morgan Healthcare Conference PR Newswire
05:04AM	Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Stock Performance Influenced By Its Fundamentals In Any Way? Simply Wall St.
Dec-28-20 09:00AM	Y-mAbs Announces Sale of Priority Review Voucher GlobeNewswire
06:00AM	United Therapeutics Announces Agreement To Acquire Priority Review Voucher PR Newswire
Dec-20-20 07:03PM	Is UTHR A Good Stock To Buy Now? Insider Monkey
Dec-15-20 04:13PM	United Therapeutics Meets 80-Plus RS Rating Benchmark; Hits New High Investor's Business Daily
Dec-09-20 06:00AM	United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis PR Newswire
Nov-27-20 11:31AM	United Therapeutics (UTHR) Up 2.3% Since Last Earnings Report: Can It Continue? Zacks
Nov-26-20 09:14AM	Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter Zacks
Nov-24-20 06:00AM	United Therapeutics Releases Its First Corporate Responsibility Report PR Newswire
Nov-10-20 06:00AM	United Therapeutics Corporation To Present At The Jefferies Virtual London Healthcare Conference PR Newswire
Nov-05-20 01:20PM	These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely Simply Wall St.
Nov-02-20 05:55AM	United Therapeutics Corporation To Present At The Credit Suisse 29th Annual Virtual Healthcare Conference PR Newswire
Oct-28-20 02:31PM	United Therapeutics Corp (UTHR) Q3 2020 Earnings Call Transcript Motley Fool +6.99%
12:13PM	United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates Zacks
07:30AM	United Therapeutics (UTHR) Q3 Earnings and Revenues Surpass Estimates Zacks
07:22AM	Recap: United Therapeutics Q3 Earnings Benzinga
07:00AM	United Therapeutics Corp. to Host Earnings Call ACCESSWIRE
06:00AM	United Therapeutics Corporation Reports Third Quarter 2020 Financial Results PR Newswire
Oct-27-20 11:59AM	Drug/Biotech Stock Q3 Earnings on Oct 28: GSK, AMGN & More Zacks
09:12AM	Was The Smart Money Right About United Therapeutics Corporation (UTHR)? Insider Monkey
Oct-22-20 06:00AM	United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting PR Newswire
Oct-21-20 06:00AM	United Therapeutics Corporation To Report Third Quarter 2020 Financial Results Before The Market Opens On Wednesday, October 28, 2020 PR Newswire
Oct-15-20 06:00AM	United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020 PR Newswire
Sep-21-20 07:00AM	CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant PR Newswire
Sep-17-20 01:01PM	How Much Did United Therapeutics'(NASDAQ:UTHR) Shareholders Earn From Share Price Movements Over The Last Five Years? Simply Wall St.
Sep-16-20 06:00AM	United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit PR Newswire
Sep-11-20 06:00AM	United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors PR Newswire
Sep-09-20 10:43AM	Hedge Funds Are Absolutely Crazy About United Therapeutics Corporation (UTHR) Insider Monkey
Aug-28-20 11:31AM	United Therapeutics (UTHR) Down 6.9% Since Last Earnings Report: Can It Rebound? Zacks
Aug-18-20 11:13AM	United Therapeutics Announces FDA Acceptance of Tyvaso sNDA Zacks
Aug-17-20 07:31AM	United Therapeutics Scores FDA Nod For New Tyvaso Review SmarterAnalyst
06:00AM	United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease PR Newswire
Aug-05-20 06:00AM	United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference PR Newswire
Jul-30-20 07:32PM	10 Biggest Biotechnology Companies Investopedia
11:41AM	United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat Zacks
Jul-29-20 08:02PM	United Therapeutics Corp (UTHR) Q2 2020 Earnings Call Transcript Motley Fool
08:47AM	United Therapeutics Corporation's (NASDAQ:UTHR) Intrinsic Value Is Potentially 73% Above Its Share Price Simply Wall St.
07:30AM	United Therapeutics (UTHR) Q2 Earnings Meet Estimates Zacks
07:23AM	Recap: United Therapeutics Q2 Earnings Benzinga
Jul-23-20 06:00AM	United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia PR Newswire
Jul-22-20 12:32PM	United Therapeutics (UTHR) Expected to Beat Earnings Estimates: Should You Buy? Zacks
06:00AM	United Therapeutics Corporation To Report Second Quarter 2020 Financial Results Before The Market Opens On Wednesday, July 29, 2020 PR Newswire
Jul-15-20 01:15PM	Steven Cohen Homes in on Otonomy GuruFocus.com
Jul-13-20 04:18PM	Did Hedge Funds Make The Right Call On United Therapeutics Corporation (UTHR) ? Insider Monkey
Jul-07-20 11:14AM	3 Perfect 10 Healthcare Stocks That Have Plenty of Growth on Tap TipRanks
Jul-06-20 10:35AM	The Perfect 10 Portfolio Rides Again GuruFocus.com
Jun-30-20 05:18PM	3 Health Care Companies That Beat the Market in the 1st Half of the Year GuruFocus.com
Jun-17-20 06:00AM	United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session PR Newswire
Jun-16-20 08:37PM	Edited Transcript of UTHR.OQ earnings conference call or presentation 29-Apr-20 1:00pm GMT Thomson Reuters StreetEvents
Jun-09-20 02:56PM	This Bullish Option Trade In United Therapeutics Stock Offers Potential 38.9% Return Investor's Business Daily
Jun-08-20 12:29PM	Vertex CEO Provided Best Value for Investors GuruFocus.com
Jun-05-20 11:06AM	Should You Avoid United Therapeutics Corporation (UTHR)? Insider Monkey
06:00AM	United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents PR Newswire
May-29-20 11:31AM	Why Is United Therapeutics (UTHR) Up 5% Since Last Earnings Report? Zacks
May-28-20 11:34AM	Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics Zacks
May-26-20 06:00AM	United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference PR Newswire
May-14-20 01:46PM	Zacks.com featured highlights include: SpartanNash, BG Foods, Regeneron, Vipshop and United Therapeutics Zacks
May-06-20 06:00AM	United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020 PR Newswire
May-04-20 02:29PM	Has United Therapeutics Corporation's (NASDAQ:UTHR) Impressive Stock Performance Got Anything to Do With Its Fundamentals? Simply Wall St.
May-01-20 12:00PM	United Therapeutics (UTHR) is a Great Momentum Stock: Should You Buy? Zacks
Apr-30-20 08:00AM	United Therapeutics (UTHR) Down Despite Q1 Earnings Beat Zacks
Apr-29-20 06:31PM	United Therapeutics Corp (UTHR) Q1 2020 Earnings Call Transcript Motley Fool
07:30AM	United Therapeutics (UTHR) Q1 Earnings and Revenues Beat Estimates Zacks
06:00AM	United Therapeutics Corporation Reports First Quarter 2020 Financial Results PR Newswire
Apr-23-20 06:00AM	United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension PR Newswire
Apr-09-20 11:00AM	Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome PR Newswire
Apr-01-20 05:50PM	United Therapeutics (UTHR) Stock Moves -0.98%: What You Should Know Zacks
Mar-27-20 02:53PM	Hedge Funds Have Never Been This Bullish On United Therapeutics Corporation (UTHR) Insider Monkey
11:30AM	United Therapeutics (UTHR) Down 8.7% Since Last Earnings Report: Can It Rebound? Zacks
Mar-16-20 11:30AM	Is United Therapeutics (UTHR) Outperforming Other Medical Stocks This Year? Zacks -13.58%
Mar-15-20 11:28PM	Edited Transcript of UTHR earnings conference call or presentation 26-Feb-20 2:00pm GMT Thomson Reuters StreetEvents
Feb-28-20 11:30AM	Is United Therapeutics (UTHR) Stock Outpacing Its Medical Peers This Year? Zacks
06:43AM	Zacks.com featured highlights include: McKesson, United Therapeutics, Virtusa and Cardinal Health Zacks
Feb-27-20 10:44AM	United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss Zacks
10:40AM	Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top Zacks
09:41AM	4 Finest Value Stocks Based on Discounted PEG Zacks
Feb-26-20 09:03AM	Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates Zacks -6.25%
07:30AM	United Therapeutics (UTHR) Lags Q4 Earnings and Revenue Estimates Zacks
Feb-25-20 08:17AM	Will United Therapeutics Continue to Surge Higher? Zacks
06:00AM	United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference PR Newswire
Feb-24-20 01:56PM	United Therapeutics gets good news and stock boost from drug candidate American City Business Journals +7.84%
06:16AM	United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin® PR Newswire
06:00AM	United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints PR Newswire
Feb-21-20 02:25PM	Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y Zacks
Feb-19-20 12:31PM	Earnings Preview: United Therapeutics (UTHR) Q4 Earnings Expected to Decline Zacks
11:13AM	Zacks.com featured highlights include: Tempur Sealy International, Twin River Worldwide, Rite Aid, DaVita and United Therapeutics Zacks
06:00AM	United Therapeutics Corporation to Report Fourth Quarter and Full Year 2019 Financial Results Before the Market Opens on Wednesday, February 26, 2020 PR Newswire
Feb-18-20 09:51AM	5 Stocks in Focus on Remarkable Relative Price Strength Zacks
Feb-14-20 10:36AM	New Strong Buy Stocks for February 14th Zacks
Feb-05-20 03:01PM	Court sides with United Therapeutics in suit from generic competitor, but doesn't dismiss case American City Business Journals
02:39PM	5 Stocks Trading Below Peter Lynch Value GuruFocus.com
11:15AM	Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod Zacks
07:43AM	The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data Benzinga
Feb-04-20 12:10PM	Why United Therapeutics (UTHR) is Poised to Beat Earnings Estimates Again Zacks
Feb-03-20 08:42AM	United Therapeutics gets disappointing news on cancer therapy American City Business Journals
06:00AM	United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint PR Newswire
Jan-17-20 08:16AM	Arena's (ARNA) Heart Failure Candidate Gets Fast Track Status Zacks

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and internationally. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing OreniPro, RemoPro, Treprostinil Technosphere, Trevyent, Ralinepag, and Aurora-GT to treat PAH; LNG01 to treat IPF; Unexisome to treat BPD; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. The company has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder, and Dreamboat and Cricket devices; Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH; and Samumed LLC to develop LNG01. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MAHON PAUL A	EVP & General Counsel	Jan 07	Option Exercise	94.96	6,000	569,760	42,131	Jan 08 04:39 PM
CAUSEY CHRISTOPHER	Director	Jan 07	Option Exercise	88.03	1,500	132,045	2,325	Jan 08 04:38 PM
CAUSEY CHRISTOPHER	Director	Jan 06	Option Exercise	88.03	1,500	132,045	2,325	Jan 08 04:38 PM
Giltner Richard	Director	Jan 06	Option Exercise	48.11	10,000	481,100	18,350	Jan 08 04:36 PM
Giltner Richard	Director	Jan 05	Option Exercise	48.11	5,000	240,550	13,350	Jan 06 04:35 PM
CAUSEY CHRISTOPHER	Director	Jan 05	Option Exercise	88.03	1,500	132,045	2,325	Jan 06 04:31 PM
CAUSEY CHRISTOPHER	Director	Dec 31	Option Exercise	88.03	7,500	660,225	8,325	Jan 04 04:30 PM
CAUSEY CHRISTOPHER	Director	Dec 23	Option Exercise	88.03	1,500	132,045	2,325	Dec 28 04:32 PM
MAHON PAUL A	EVP & General Counsel	Dec 17	Option Exercise	94.96	6,000	569,760	42,131	Dec 18 04:58 PM
Giltner Richard	Director	Dec 17	Option Exercise	54.77	5,000	273,850	13,350	Dec 18 04:56 PM
PATUSKY CHRISTOPHER	Director	Dec 08	Option Exercise	63.90	3,000	191,700	5,300	Dec 09 04:31 PM
MAHON PAUL A	EVP & General Counsel	Dec 03	Option Exercise	94.96	6,000	569,760	42,131	Dec 04 04:51 PM
DWEK RAYMOND	Director	Nov 10	Option Exercise	48.11	2,000	96,220	2,000	Nov 12 04:33 PM
MAHON PAUL A	EVP & General Counsel	Nov 05	Option Exercise	94.96	6,000	569,760	42,131	Nov 06 04:31 PM
Giltner Richard	Director	Nov 04	Option Exercise	54.77	5,000	273,850	13,350	Nov 05 04:33 PM
DWEK RAYMOND	Director	Nov 02	Option Exercise	54.77	5,000	273,850	5,000	Nov 03 04:44 PM
BENKOWITZ MICHAEL	President and COO	Nov 02	Option Exercise	63.42	28,200	1,788,420	23,748	Nov 03 04:43 PM
CAUSEY CHRISTOPHER	Director	Oct 28	Option Exercise	63.90	2,000	127,800	2,825	Oct 29 04:32 PM
CAUSEY CHRISTOPHER	Director	Oct 22	Option Exercise	63.90	2,500	159,750	3,325	Oct 23 04:32 PM
CAUSEY CHRISTOPHER	Director	Oct 16	Option Exercise	63.90	2,250	143,775	2,325	Oct 19 04:33 PM
PATUSKY CHRISTOPHER	Director	Aug 05	Option Exercise	54.77	5,000	273,850	7,300	Aug 06 06:13 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 09	Option Exercise	63.22	4,834	305,605	4,974	Jul 09 07:58 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 09	Sale	117.04	4,834	565,782	140	Jul 09 07:58 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 08	Option Exercise	63.22	10,000	632,200	10,140	Jul 08 07:54 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 08	Sale	117.91	10,000	1,179,051	140	Jul 08 07:54 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 07	Option Exercise	63.22	10,000	632,200	10,140	Jul 08 07:54 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 07	Sale	119.31	10,000	1,193,095	140	Jul 08 07:54 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 06	Option Exercise	63.22	10,000	632,200	10,140	Jul 08 07:54 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 06	Sale	119.60	10,000	1,196,030	140	Jul 08 07:54 PM
CAUSEY CHRISTOPHER	Director	Jul 02	Option Exercise	63.90	750	47,925	1,575	Jul 06 08:04 AM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 02	Option Exercise	63.22	10,000	632,200	10,140	Jul 02 04:58 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 02	Sale	120.73	10,000	1,207,257	140	Jul 02 04:58 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 01	Option Exercise	63.22	10,000	632,200	10,140	Jul 02 04:58 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jul 01	Sale	121.39	10,000	1,213,877	140	Jul 02 04:58 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 30	Option Exercise	63.22	10,000	632,200	10,140	Jul 01 07:14 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 30	Sale	120.36	10,000	1,203,586	140	Jul 01 07:14 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 29	Option Exercise	63.22	10,000	632,200	10,140	Jul 01 07:14 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 29	Sale	120.01	10,000	1,200,103	140	Jul 01 07:14 PM
DWEK RAYMOND	Director	Jun 29	Sale	116.81	4,600	537,323	0	Jun 30 01:56 PM
DWEK RAYMOND	Director	Jun 26	Option Exercise	0.00	4,600	0	4,600	Jun 30 01:56 PM
PATUSKY CHRISTOPHER	Director	Jun 26	Option Exercise	0.00	2,300	0	2,300	Jun 30 02:03 PM
SULLIVAN LOUIS W	Director	Jun 26	Option Exercise	0.00	2,300	0	9,420	Jun 30 02:03 PM
Olian Judy D.	Director	Jun 26	Option Exercise	0.00	2,300	0	5,790	Jun 30 02:02 PM
Mesa Nilda	Director	Jun 26	Option Exercise	0.00	2,300	0	4,960	Jun 30 01:59 PM
KURZWEIL RAY	Director	Jun 26	Option Exercise	0.00	2,300	0	7,540	Jun 30 01:59 PM
Giltner Richard	Director	Jun 26	Option Exercise	0.00	4,600	0	8,350	Jun 30 01:57 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 26	Option Exercise	63.22	10,000	632,200	10,140	Jun 26 05:39 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 26	Sale	121.00	10,000	1,210,047	140	Jun 26 05:39 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 25	Option Exercise	63.22	10,000	632,200	10,140	Jun 26 05:39 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 25	Sale	125.06	10,000	1,250,607	140	Jun 26 05:39 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 24	Option Exercise	63.22	10,000	632,200	10,140	Jun 24 05:34 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 24	Sale	120.34	10,000	1,203,404	140	Jun 24 05:34 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 23	Option Exercise	63.22	10,000	632,200	10,140	Jun 24 05:34 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 23	Sale	120.46	10,000	1,204,650	140	Jun 24 05:34 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 22	Option Exercise	63.22	10,000	632,200	10,140	Jun 24 05:34 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 22	Sale	117.81	10,000	1,178,100	140	Jun 24 05:34 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 19	Option Exercise	63.22	10,000	632,200	10,140	Jun 19 05:38 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 19	Sale	116.76	10,000	1,167,568	140	Jun 19 05:38 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 18	Option Exercise	63.22	10,000	632,200	10,140	Jun 19 05:38 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 18	Sale	115.95	10,000	1,159,453	140	Jun 19 05:38 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 17	Option Exercise	63.22	10,000	632,200	10,140	Jun 17 06:00 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 17	Sale	117.82	10,000	1,178,173	140	Jun 17 06:00 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 16	Option Exercise	63.22	10,000	632,200	10,140	Jun 17 06:00 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 16	Sale	114.31	10,000	1,143,148	140	Jun 17 06:00 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 15	Option Exercise	63.22	10,000	632,200	10,140	Jun 17 06:00 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 15	Sale	113.87	10,000	1,138,662	140	Jun 17 06:00 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 12	Option Exercise	63.22	10,000	632,200	10,140	Jun 12 05:02 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 12	Sale	115.69	10,000	1,156,897	140	Jun 12 05:02 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 11	Option Exercise	63.22	10,000	632,200	10,140	Jun 12 05:02 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 11	Sale	118.03	10,000	1,180,302	140	Jun 12 05:02 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 10	Option Exercise	63.22	10,000	632,200	10,140	Jun 10 04:49 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 10	Sale	124.78	10,000	1,247,834	140	Jun 10 04:49 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 09	Option Exercise	63.22	10,000	632,200	10,140	Jun 10 04:49 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 09	Sale	125.69	10,000	1,256,950	140	Jun 10 04:49 PM
Thompson Tommy G	Director	Jun 09	Sale	126.79	4,210	533,806	9,790	Jun 10 04:50 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 08	Option Exercise	63.22	10,000	632,200	10,140	Jun 10 04:49 PM
Olian Judy D.	Director	Jun 08	Sale	124.96	4,510	563,591	3,490	Jun 08 06:38 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 08	Sale	124.75	10,000	1,247,525	140	Jun 10 04:49 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 05	Option Exercise	63.22	10,000	632,200	10,140	Jun 05 06:53 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 05	Sale	123.59	10,000	1,235,862	140	Jun 05 06:53 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 04	Option Exercise	63.22	10,000	632,200	10,140	Jun 05 06:53 PM
CAUSEY CHRISTOPHER	Director	Jun 04	Option Exercise	63.90	750	47,925	1,575	Jun 05 06:18 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 04	Sale	123.55	10,000	1,235,493	140	Jun 05 06:53 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 03	Option Exercise	63.22	10,000	632,200	10,140	Jun 03 06:28 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 03	Sale	124.52	10,000	1,245,215	140	Jun 03 06:28 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 02	Option Exercise	63.22	10,000	632,200	10,140	Jun 03 06:28 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 02	Sale	121.79	10,000	1,217,916	140	Jun 03 06:28 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 01	Option Exercise	63.22	10,000	632,200	10,140	Jun 03 06:28 PM
ROTHBLATT MARTINE A	Chairman & CEO	Jun 01	Sale	119.28	10,000	1,192,762	140	Jun 03 06:28 PM
ROTHBLATT MARTINE A	Chairman & CEO	May 29	Option Exercise	63.22	10,000	632,200	10,140	Jun 01 08:07 AM
ROTHBLATT MARTINE A	Chairman & CEO	May 29	Sale	115.91	10,000	1,159,091	140	Jun 01 08:07 AM
ROTHBLATT MARTINE A	Chairman & CEO	May 28	Option Exercise	63.22	10,000	632,200	10,140	Jun 01 08:07 AM
ROTHBLATT MARTINE A	Chairman & CEO	May 28	Sale	116.28	10,000	1,162,839	140	Jun 01 08:07 AM
ROTHBLATT MARTINE A	Chairman & CEO	May 27	Option Exercise	63.22	10,000	632,200	10,140	May 27 06:20 PM
ROTHBLATT MARTINE A	Chairman & CEO	May 27	Sale	115.90	10,000	1,159,025	140	May 27 06:20 PM
ROTHBLATT MARTINE A	Chairman & CEO	May 26	Option Exercise	63.22	10,000	632,200	10,140	May 27 06:20 PM
ROTHBLATT MARTINE A	Chairman & CEO	May 26	Sale	119.65	10,000	1,196,475	140	May 27 06:20 PM
ROTHBLATT MARTINE A	Chairman & CEO	May 22	Option Exercise	63.22	10,000	632,200	10,140	May 22 05:04 PM
ROTHBLATT MARTINE A	Chairman & CEO	May 22	Sale	117.30	10,000	1,173,015	140	May 22 05:04 PM
ROTHBLATT MARTINE A	Chairman & CEO	May 21	Option Exercise	63.22	10,000	632,200	10,140	May 22 05:04 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience